Released Nov 4, 2019, after the close
10-Q filed Nov 4, 2019, 35 days after period end · 0001564590-19-039770
Q3 2019 · 10-Q
Revenue$172.00K$172.00K −73.9% vs Q3 2018+156.7% vs Q2 2019
Net Income-$17.70M-$17.70M N/M vs Q3 2018N/M vs Q2 2019
EPS Diluted-$0.95-$0.95 N/M vs Q3 2018N/M vs Q2 2019
Operating Income-$17,985,000N/M
Operating Cash Flowderived-$9,659,000N/M
Free Cash Flowderived-$9,676,000—
Margins · derived
Operating margin-10456.4%−8794.5 pt vs Q3 2018
Net margin-10290.7%−8700.6 pt vs Q3 2018
What the release said
The release
Same quarter
| Metric | Q3 2019 | Q3 2018 | Q3 2017 | Q3 2016 |
|---|---|---|---|---|
| Revenue | $172.00K | $658.00K | $597.00K | — |
| Net Income | -$17.70M | -$10.46M | -$9.84M | -$6.32M |
| EPS Diluted | -$0.95 | -$0.60 | -$36.02 | -$23.23 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR